Spyre Therapeutics Inc (SYRE)

$23.50 +0.87 (3.84%)
Market Cap 1.37B
Revenue (ttm) 0.00
Net Income (ttm) -208.02M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 543,500
Avg Vol 943,386
Day's Range N/A - N/A
Shares Out 60.40M
Stochastic %K 70%
Beta 2.99
Analysts Strong Sell
Price Target $52.64

Company Profile

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and S...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 651 5940
Address:
221 Crescent Street, Building 23 Suite 105, Waltham, United States
BEATOFtheMARKET
BEATOFtheMARKET Nov. 9 at 11:11 PM
$SXI $SYF $SYK $SYRE $T
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 6 at 5:56 PM
$SYRE $T $TARK $TBBK $TCBI
0 · Reply
d_risk
d_risk Nov. 4 at 10:26 PM
$SYRE - Spyre Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors SYRE’s 10-Q risk factors for 2025 add new sections on government regulation, internal controls, and product liability; expand on regulatory, IP, and cybersecurity threats; detail risks from government shutdowns, capital needs, and global volatility; and highlight recent material weaknesses, while removing some prior market and management risks. #Biotechnology #GlobalVolatility #CapitalNeeds #CybersecurityThreats #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/SYRE/10-Q/2025-11-04
0 · Reply
IOANNISMICHAEL
IOANNISMICHAEL Oct. 31 at 10:46 AM
$SYRE anyone knows what’s going on?
0 · Reply
OnlyFibs
OnlyFibs Oct. 25 at 1:04 AM
$SYRE - Spyre Therapeutics - Bullish - Golden Cross 50/200sma crossover - Consecutive weeks of buyers - accumulation - Bulls need to claim $25 to confirm more upside - Add to your WL #hovdid
0 · Reply
oaksapollo
oaksapollo Oct. 14 at 5:21 PM
$SYRE I don't understand this company. All they're doing is making YTE versions of existing drugs, but there is no IP around YTE, so anyone can go do this. Isn't it a no brainer for the manufacturers of the existing drugs to go make their own YTE versions? For example, why wouldn't Abbvie go make a YTE version of Skyrizi? Nothing is stopping them. I don't quite understand the $1.3B cap. It seems like a zero to me. What does Spyre have that is unique and special?
0 · Reply
Pika_Capital
Pika_Capital Oct. 14 at 2:44 PM
$ORKA $APGE $SYRE reminder
1 · Reply
AlertsAndNews
AlertsAndNews Oct. 14 at 2:41 AM
$SYRE Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock Spyre Therapeutics announced the pricing of its underwritten public offering of 14,864,865 shares of common stock at $18.50 per share, for total gross proceeds of approximately $275 million.
0 · Reply
Pika_Capital
Pika_Capital Oct. 14 at 1:21 AM
$SYRE I expect strong demand during offering as for $APGE Stock is green AH, tomorrow should be interesting
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Oct. 13 at 8:33 PM
$SYRE
0 · Reply
Latest News on SYRE
Spyre Therapeutics Announces Grants of Inducement Awards

Nov 7, 2025, 4:05 PM EST - 7 days ago

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 4, 2025, 4:05 PM EST - 10 days ago

Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody

Nov 4, 2025, 4:01 PM EST - 10 days ago

Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody

Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025

Oct 24, 2025, 8:00 AM EDT - 21 days ago

Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million

Oct 15, 2025, 4:15 PM EDT - 4 weeks ago

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million

Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock

Oct 13, 2025, 9:07 PM EDT - 4 weeks ago

Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants

Oct 13, 2025, 4:01 PM EDT - 4 weeks ago

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants

Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025

Oct 5, 2025, 9:00 AM EDT - 5 weeks ago

Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025

Intelligent Development Could Make Spyre Therapeutics Best In Show

Sep 18, 2025, 10:34 PM EDT - 2 months ago

Intelligent Development Could Make Spyre Therapeutics Best In Show

Spyre Therapeutics to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum

Sep 8, 2025, 4:05 PM EDT - 2 months ago

Spyre Therapeutics to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum

Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 5, 2025, 4:02 PM EDT - 3 months ago

Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward

Jun 18, 2025, 2:58 PM EDT - 5 months ago

Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward

Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts

Jun 17, 2025, 7:30 AM EDT - 5 months ago

Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025

Jun 16, 2025, 4:05 PM EDT - 5 months ago

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025

Spyre Therapeutics to Participate in Upcoming June Investor Conferences

May 28, 2025, 8:30 AM EDT - 6 months ago

Spyre Therapeutics to Participate in Upcoming June Investor Conferences

Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 4:05 PM EDT - 6 months ago

Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001

May 5, 2025, 8:00 AM EDT - 6 months ago

Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001

Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody

Mar 27, 2025, 4:05 PM EDT - 8 months ago

Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody

Spyre Therapeutics: Targeting The Future Of IBD Treatment

Mar 4, 2025, 4:51 AM EST - 9 months ago

Spyre Therapeutics: Targeting The Future Of IBD Treatment

Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Feb 27, 2025, 4:05 PM EST - 9 months ago

Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Spyre Therapeutics to Participate in Upcoming March Investor Conferences

Feb 25, 2025, 8:00 AM EST - 9 months ago

Spyre Therapeutics to Participate in Upcoming March Investor Conferences

Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation

Feb 19, 2025, 8:00 AM EST - 9 months ago

Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation

Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts

Jan 13, 2025, 8:00 AM EST - 10 months ago

Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts

Spyre Therapeutics Added to the Nasdaq Biotechnology Index

Dec 18, 2024, 8:00 AM EST - 11 months ago

Spyre Therapeutics Added to the Nasdaq Biotechnology Index

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Shareholders to Learn More About the Investigation

Dec 4, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Shareholders to Learn More About the Investigation

Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Dec 3, 2024, 10:00 AM EST - 1 year ago

Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Shareholders to Inquire about Securities Investigation

Dec 2, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Shareholders to Inquire about Securities Investigation

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies

Dec 2, 2024, 8:00 AM EST - 1 year ago

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies

Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Shareholders to Connect

Dec 1, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Stockholders to Inquire about Securities Investigation

Nov 29, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Investors to Learn More About the Investigation

Nov 28, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Investors to Learn More About the Investigation

Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Nov 27, 2024, 10:00 AM EST - 1 year ago

Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Connect

Nov 26, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Connect

Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Nov 25, 2024, 5:11 PM EST - 1 year ago

Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Stockholders to Connect

Nov 25, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Stockholders to Connect

Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Nov 24, 2024, 10:00 AM EST - 1 year ago

Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Stockholders to Learn More About the Investigation

Nov 22, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Investors to Inquire about Securities Investigation

Nov 21, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Reach Out

Nov 20, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Reach Out

Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock

Nov 18, 2024, 9:18 PM EST - 1 year ago

Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock

Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential for Both Q3M & Q6M Maintenance Dosing

Nov 12, 2024, 7:30 AM EST - 1 year ago

Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential for Both Q3M & Q6M Maintenance Dosing

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024

Nov 11, 2024, 4:05 PM EST - 1 year ago

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024

Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 7, 2024, 4:05 PM EST - 1 year ago

Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Spyre Therapeutics to Participate in Upcoming November Investor Conferences

Oct 30, 2024, 4:05 PM EDT - 1 year ago

Spyre Therapeutics to Participate in Upcoming November Investor Conferences

Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations

Oct 14, 2024, 8:00 AM EDT - 1 year ago

Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations

BEATOFtheMARKET
BEATOFtheMARKET Nov. 9 at 11:11 PM
$SXI $SYF $SYK $SYRE $T
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 6 at 5:56 PM
$SYRE $T $TARK $TBBK $TCBI
0 · Reply
d_risk
d_risk Nov. 4 at 10:26 PM
$SYRE - Spyre Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors SYRE’s 10-Q risk factors for 2025 add new sections on government regulation, internal controls, and product liability; expand on regulatory, IP, and cybersecurity threats; detail risks from government shutdowns, capital needs, and global volatility; and highlight recent material weaknesses, while removing some prior market and management risks. #Biotechnology #GlobalVolatility #CapitalNeeds #CybersecurityThreats #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/SYRE/10-Q/2025-11-04
0 · Reply
IOANNISMICHAEL
IOANNISMICHAEL Oct. 31 at 10:46 AM
$SYRE anyone knows what’s going on?
0 · Reply
OnlyFibs
OnlyFibs Oct. 25 at 1:04 AM
$SYRE - Spyre Therapeutics - Bullish - Golden Cross 50/200sma crossover - Consecutive weeks of buyers - accumulation - Bulls need to claim $25 to confirm more upside - Add to your WL #hovdid
0 · Reply
oaksapollo
oaksapollo Oct. 14 at 5:21 PM
$SYRE I don't understand this company. All they're doing is making YTE versions of existing drugs, but there is no IP around YTE, so anyone can go do this. Isn't it a no brainer for the manufacturers of the existing drugs to go make their own YTE versions? For example, why wouldn't Abbvie go make a YTE version of Skyrizi? Nothing is stopping them. I don't quite understand the $1.3B cap. It seems like a zero to me. What does Spyre have that is unique and special?
0 · Reply
Pika_Capital
Pika_Capital Oct. 14 at 2:44 PM
$ORKA $APGE $SYRE reminder
1 · Reply
AlertsAndNews
AlertsAndNews Oct. 14 at 2:41 AM
$SYRE Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock Spyre Therapeutics announced the pricing of its underwritten public offering of 14,864,865 shares of common stock at $18.50 per share, for total gross proceeds of approximately $275 million.
0 · Reply
Pika_Capital
Pika_Capital Oct. 14 at 1:21 AM
$SYRE I expect strong demand during offering as for $APGE Stock is green AH, tomorrow should be interesting
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Oct. 13 at 8:33 PM
$SYRE
0 · Reply
DonCorleone77
DonCorleone77 Oct. 13 at 8:04 PM
$SYRE Spyre Therapeutics announces common stock offering, no amount given
0 · Reply
Whiskey1679
Whiskey1679 Oct. 11 at 6:46 PM
Whiskey's Penny Picks out Monday approx. 6:00 am PDT!! Also with China Trump Tariffs a shift in market sentiment on where to invest... Google: best industries to invest today with Trump China Tariffs Defense/Aerospace, Consumer Goods, Healthcare/Telemedicine, Earth Minerals, Energy Steel/Aluminum, Membership clubs seem to be the way to with Trump China Tariffs shifting market sentiment. vehicles. Rare earth mineral miners can benefit from tariffs, which encourage local battery production. Energy: Tariffs on foreign energy sources can boost domestic oil and gas producers. Friday's After Hour Gainers: $FORA $PMAX $VIVK $SYRE $CRML
0 · Reply
FennickTradings
FennickTradings Oct. 11 at 4:08 PM
$SYRE anyone part of the CVR group?
0 · Reply
FennickTradings
FennickTradings Oct. 11 at 3:39 PM
$SYRE on 19 august I achieved random dividend, does anyone know why?
0 · Reply
StockScanners
StockScanners Oct. 10 at 1:49 AM
$SYRE keep watch if this holds above 19.50
0 · Reply
x1fisher
x1fisher Oct. 9 at 4:54 PM
QTTB will be the next 5X Biotech squeeze - Massive short interest on a locked up nano float - Cash runaway into 2027 - P2 Data coming up - Bullish chart indicating a historic reversal and was trading over $50 a year ago! $OPEN $ARAI $NEOG $TELO $SYRE ww
1 · Reply
Pika_Capital
Pika_Capital Oct. 9 at 4:25 PM
$ORKA $APGE $SYRE every day of waiting costs you 💰💰
1 · Reply
Money_never_sleep
Money_never_sleep Oct. 9 at 4:08 PM
$SYRE $30
0 · Reply
Pika_Capital
Pika_Capital Oct. 8 at 4:53 PM
$ORKA $APGE $SYRE reminder 🚀
0 · Reply
Mamma_m1a
Mamma_m1a Oct. 8 at 4:52 PM
$SYRE Bullish Bloomberg:
0 · Reply
Quantumup
Quantumup Oct. 7 at 12:37 PM
Guggenheim reiterated $SYRE Buy-$65-Top Pick after hosting a dinner at UEGW with investors and SYRE's CEO (Cameron Turtle) and CMO (Sheldon Sloan). $JNJ $ABBV Guggenheim said in its note to investors:
0 · Reply
Mamma_m1a
Mamma_m1a Oct. 4 at 8:31 AM
$SYRE Bullish.
0 · Reply